Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 18;14(1):21758.
doi: 10.1038/s41598-024-71413-3.

UPLC-PDA factorial design assisted method for simultaneous determination of oseltamivir, dexamethasone, and remdesivir in human plasma

Affiliations

UPLC-PDA factorial design assisted method for simultaneous determination of oseltamivir, dexamethasone, and remdesivir in human plasma

Hanan I El-Shorbagy et al. Sci Rep. .

Abstract

A green and simple UPLC method was developed and optimized, adopting a factorial design for simultaneous determination of oseltamivir phosphate and remdesivir with dexamethasone as a co-administered drug in human plasma and using daclatasvir dihydrochloride as an internal standard within 5 min. The separation was established on UPLC column BEH C18 1.7 μm (2.1 × 100.0 mm) connected to UPLC pre-column BEH 1.7 μm (2.1 × 5.0 mm) at 50 °C with an injection volume of 10 μL. The photodiode array detector (PDA) was set at three wavelengths of 220, 315, and 245 nm for oseltamivir phosphate, the internal standard, and both dexamethasone and remdesivir, respectively. The mobile phase consisted of methanol and ammonium acetate solution (40 mM) adjusted to pH 4 in a ratio of 61.5:38.5 (v/v) with a flow rate of 0.25 mL min-1. The calibration curves were linear over 500.0-5000.0 ng mL-1 for oseltamivir phosphate, over 10.0-500.0 ng mL-1 and 500.0-5000.0 ng mL-1 for dexamethasone, and over 20.0-500 ng mL-1 and 500.0-5000.0 ng mL-1 for remdesivir. The Gibbs free energy and Van't Hoff plots were used to investigate the effect of column oven temperatures on retention times. Fluoride-EDTA anticoagulant showed inhibition activity on the esterase enzyme in plasma. The proposed method was validated according to the M10 ICH, FDA, and EMA's bioanalytical guidelines. According to Eco-score, GAPI, and AGREE criteria, the proposed method was considered acceptable green.

Keywords: Fluoride-EDTA plasma; Gibbs free energy; Green analysis; UPLC-PDA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Residual plots for k' (OSTP) and RS2 (DAC).
Fig. 2
Fig. 2
UPLC Chromatograms of oseltamivir phosphate, dexamethasone, daclatasvir dihydrochrolide (IS), and remdesivir (500 ng mL−1 each) were simultaneously separated at different column champer’s temperatures (25, 30, 45, and 50 °C) (each peak labeled by (Rt-T-N)).
Fig. 3
Fig. 3
Van’t Hoff plots of oseltamivir phosphate, dexamethasone, daclatasvir dihydrochrolide (IS), and remdesivir.
Fig. 4
Fig. 4
Chromatograms of 30% (v/v) aqueous methanol (blank), oseltamivir phosphate, dexamethasone, daclatasvir dihydrochrolide (IS), and remdesivir (500 ng mL−1 each) at different PDA channels (220, 245, and 315 nm) and column temperature of 50 °C.
Fig. 5
Fig. 5
Chromatograms of plasma extracted by the proposed method for specificity.

Similar articles

References

    1. Gulyaeva, A. A. & Gorbalenya, A. E. A nidovirus perspective on SARS-CoV-2. Biochem. Biophys. Res. Commun.538, 24–34 (2021). - PMC - PubMed
    1. Malone, B., Urakova, N., Snijder, E. J. & Campbell, E. A. Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol.23, 21–39. 10.1038/s41580-021-00432-z (2022). - PMC - PubMed
    1. Shabani, M., Sadegh Ehdaei, B., Fathi, F. & Dowran, R. A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019. New Microbes New Infect.42, 100895. 10.1016/j.nmni.2021.100895 (2021). - PMC - PubMed
    1. Vafaei, S., Razmi, M., Mansoori, M., Asadi-Lari, M. & Madjd, Z. Spotlight of remdesivir in comparison with ribavirin, favipiravir, oseltamivir and umifenovir in coronavirus disease 2019 (COVID-19) pandemic. Lancet Infect. Dis.10.2139/ssrn.3569866 (2020).
    1. Tan, Q. et al. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. Bioorg. Chem.104, 104257. 10.1016/j.bioorg.2020.104257 (2020). - PMC - PubMed

MeSH terms

LinkOut - more resources